nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomethadyl Acetate—CYP19A1—osteoporosis	0.572	1	CbGaD
Levomethadyl Acetate—CYP19A1—Raloxifene—osteoporosis	0.151	0.359	CbGbCtD
Levomethadyl Acetate—CYP3A7—Estradiol—osteoporosis	0.0406	0.0967	CbGbCtD
Levomethadyl Acetate—CYP3A7-CYP3A51P—Estradiol—osteoporosis	0.0406	0.0967	CbGbCtD
Levomethadyl Acetate—CYP3A5—Estradiol—osteoporosis	0.0304	0.0725	CbGbCtD
Levomethadyl Acetate—CYP3A4—Estropipate—osteoporosis	0.0286	0.0681	CbGbCtD
Levomethadyl Acetate—CYP3A4—Calcitriol—osteoporosis	0.0286	0.0681	CbGbCtD
Levomethadyl Acetate—CYP3A4—Ergocalciferol—osteoporosis	0.0228	0.0544	CbGbCtD
Levomethadyl Acetate—CYP3A4—Raloxifene—osteoporosis	0.0191	0.0454	CbGbCtD
Levomethadyl Acetate—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0184	0.0439	CbGbCtD
Levomethadyl Acetate—CYP3A4—Cholecalciferol—osteoporosis	0.0147	0.0351	CbGbCtD
Levomethadyl Acetate—CYP3A4—Conjugated Estrogens—osteoporosis	0.0135	0.0322	CbGbCtD
Levomethadyl Acetate—CYP3A4—Estradiol—osteoporosis	0.0119	0.0283	CbGbCtD
Levomethadyl Acetate—Loperamide—POMC—osteoporosis	0.00119	0.509	CrCbGaD
Levomethadyl Acetate—Tamoxifen—ESR2—osteoporosis	0.00039	0.166	CrCbGaD
Levomethadyl Acetate—Tamoxifen—CYP19A1—osteoporosis	0.000261	0.111	CrCbGaD
Levomethadyl Acetate—Methadone—CYP19A1—osteoporosis	0.000259	0.11	CrCbGaD
Levomethadyl Acetate—Tamoxifen—ESR1—osteoporosis	0.00024	0.103	CrCbGaD
Levomethadyl Acetate—CHRNB4—SIDS Susceptibility Pathways—GAPDH—osteoporosis	0.00011	0.0183	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—IL4-mediated signaling events—COL1A2—osteoporosis	0.000108	0.0179	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000106	0.0177	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Ovarian Infertility Genes—VDR—osteoporosis	9.97e-05	0.0166	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	9.24e-05	0.0153	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Endogenous sterols—POMC—osteoporosis	8.93e-05	0.0148	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—IL4-mediated signaling events—COL1A1—osteoporosis	8.28e-05	0.0138	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	8.24e-05	0.0137	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	8.13e-05	0.0135	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—G-protein activation—POMC—osteoporosis	7.93e-05	0.0132	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—SIDS Susceptibility Pathways—ESR2—osteoporosis	7.63e-05	0.0127	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—TCR Signaling Pathway—NFATC1—osteoporosis	7.6e-05	0.0126	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism of steroid hormones and vitamin D—POMC—osteoporosis	6.69e-05	0.0111	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	6.68e-05	0.0111	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	6.17e-05	0.0102	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	5.99e-05	0.00994	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	5.91e-05	0.00981	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Biological oxidations—CYP27A1—osteoporosis	5.65e-05	0.00939	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	5.64e-05	0.00937	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metapathway biotransformation—CYP27A1—osteoporosis	5.58e-05	0.00926	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Integrated Breast Cancer Pathway—RAP1A—osteoporosis	5.1e-05	0.00847	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Biological oxidations—CYP27A1—osteoporosis	4.91e-05	0.00815	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	4.86e-05	0.00806	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—IL4-mediated signaling events—IRS2—osteoporosis	4.85e-05	0.00805	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metapathway biotransformation—CYP27A1—osteoporosis	4.84e-05	0.00804	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	4.83e-05	0.00801	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—Transmission across Chemical Synapses—ADCY5—osteoporosis	4.64e-05	0.0077	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Opioid Signalling—ADCY5—osteoporosis	4.48e-05	0.00743	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	4.33e-05	0.00719	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	4.27e-05	0.00709	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Transmission across Chemical Synapses—ADCY5—osteoporosis	4.24e-05	0.00704	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—CALCR—osteoporosis	4.24e-05	0.00704	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—PTH1R—osteoporosis	4.24e-05	0.00704	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—IL4-mediated signaling events—IRS1—osteoporosis	4.23e-05	0.00703	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	4.15e-05	0.00688	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—SIDS Susceptibility Pathways—IL6R—osteoporosis	4.06e-05	0.00674	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	3.83e-05	0.00636	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	3.78e-05	0.00628	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	3.78e-05	0.00628	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	3.61e-05	0.00599	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	3.6e-05	0.00598	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—G alpha (i) signalling events—CNR2—osteoporosis	3.59e-05	0.00595	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	3.58e-05	0.00595	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—Neuronal System—ADCY5—osteoporosis	3.55e-05	0.0059	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Biological oxidations—CYP27A1—osteoporosis	3.55e-05	0.00589	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	3.51e-05	0.00583	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metapathway biotransformation—CYP27A1—osteoporosis	3.5e-05	0.00581	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Phase 1 - Functionalization of compounds—POMC—osteoporosis	3.36e-05	0.00558	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	3.33e-05	0.00552	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Opioid Signalling—POMC—osteoporosis	3.29e-05	0.00547	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Neuronal System—ADCY5—osteoporosis	3.25e-05	0.0054	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	3.11e-05	0.00516	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—SIDS Susceptibility Pathways—IL1B—osteoporosis	3.09e-05	0.00513	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Phase 1 - Functionalization of compounds—POMC—osteoporosis	2.92e-05	0.00484	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	2.85e-05	0.00473	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	2.79e-05	0.00463	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	2.77e-05	0.0046	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	2.72e-05	0.00451	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	2.6e-05	0.00432	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Biological oxidations—CYP19A1—osteoporosis	2.58e-05	0.00428	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metapathway biotransformation—CYP19A1—osteoporosis	2.54e-05	0.00422	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	2.49e-05	0.00413	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—CALCR—osteoporosis	2.4e-05	0.00398	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—PTH1R—osteoporosis	2.4e-05	0.00398	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—TCR Signaling Pathway—IL1B—osteoporosis	2.25e-05	0.00373	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—SIDS Susceptibility Pathways—TNF—osteoporosis	2.24e-05	0.00372	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—PTH—osteoporosis	2.23e-05	0.0037	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Integrated Breast Cancer Pathway—ESR1—osteoporosis	2.2e-05	0.00366	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—CALCR—osteoporosis	2.18e-05	0.00361	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—PTH1R—osteoporosis	2.18e-05	0.00361	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	2.17e-05	0.0036	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—CNR2—osteoporosis	2.17e-05	0.0036	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Phase 1 - Functionalization of compounds—POMC—osteoporosis	2.11e-05	0.0035	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Integrated Breast Cancer Pathway—IRS1—osteoporosis	2.06e-05	0.00342	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—WNT1—osteoporosis	2.04e-05	0.00339	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	2.01e-05	0.00334	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	1.99e-05	0.0033	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—G alpha (i) signalling events—ADCY5—osteoporosis	1.91e-05	0.00317	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—MGLL—osteoporosis	1.9e-05	0.00316	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Biological oxidations—CYP19A1—osteoporosis	1.86e-05	0.0031	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	1.85e-05	0.00307	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—PTHLH—osteoporosis	1.85e-05	0.00306	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metapathway biotransformation—CYP19A1—osteoporosis	1.84e-05	0.00305	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—SIDS Susceptibility Pathways—IL6—osteoporosis	1.81e-05	0.003	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Biological oxidations—POMC—osteoporosis	1.79e-05	0.00296	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—TCR Signaling Pathway—TGFB1—osteoporosis	1.75e-05	0.0029	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—MGLL—osteoporosis	1.73e-05	0.00287	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—PKM—osteoporosis	1.68e-05	0.0028	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—FDPS—osteoporosis	1.68e-05	0.0028	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Peptide ligand-binding receptors—POMC—osteoporosis	1.66e-05	0.00276	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	1.65e-05	0.00274	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	1.63e-05	0.00271	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	1.63e-05	0.0027	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—CALCA—osteoporosis	1.63e-05	0.0027	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—GPD2—osteoporosis	1.6e-05	0.00265	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—PGLS—osteoporosis	1.6e-05	0.00265	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Biological oxidations—POMC—osteoporosis	1.55e-05	0.00257	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—FDPS—osteoporosis	1.46e-05	0.00243	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—PKM—osteoporosis	1.46e-05	0.00243	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—ATIC—osteoporosis	1.46e-05	0.00242	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—PNP—osteoporosis	1.46e-05	0.00242	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—SOST—osteoporosis	1.42e-05	0.00236	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—G alpha (i) signalling events—POMC—osteoporosis	1.4e-05	0.00233	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—GPD2—osteoporosis	1.39e-05	0.0023	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—PGLS—osteoporosis	1.39e-05	0.0023	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—TCR Signaling Pathway—IL6—osteoporosis	1.31e-05	0.00218	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—CALCR—osteoporosis	1.29e-05	0.00213	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—PTH1R—osteoporosis	1.29e-05	0.00213	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—ATIC—osteoporosis	1.27e-05	0.0021	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—PNP—osteoporosis	1.27e-05	0.0021	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—PTH—osteoporosis	1.26e-05	0.00209	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—CA2—osteoporosis	1.24e-05	0.00206	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—OXCT1—osteoporosis	1.24e-05	0.00206	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—CNR2—osteoporosis	1.23e-05	0.00204	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	1.21e-05	0.00201	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—MGLL—osteoporosis	1.21e-05	0.00201	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Integrated Breast Cancer Pathway—MYC—osteoporosis	1.15e-05	0.0019	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—PTH—osteoporosis	1.14e-05	0.0019	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Biological oxidations—POMC—osteoporosis	1.12e-05	0.00186	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	1.12e-05	0.00185	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—CNR2—osteoporosis	1.11e-05	0.00185	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—CA2—osteoporosis	1.08e-05	0.00179	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—OXCT1—osteoporosis	1.08e-05	0.00179	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—PKM—osteoporosis	1.06e-05	0.00175	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—FDPS—osteoporosis	1.06e-05	0.00175	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—MGLL—osteoporosis	1.05e-05	0.00174	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—WNT1—osteoporosis	1.05e-05	0.00174	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—PTHLH—osteoporosis	1.04e-05	0.00173	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—IDH2—osteoporosis	1.03e-05	0.00171	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—MGLL—osteoporosis	1.02e-05	0.0017	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—PGLS—osteoporosis	1e-05	0.00166	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—GPD2—osteoporosis	1e-05	0.00166	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—LRP5—osteoporosis	9.97e-06	0.00165	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	9.81e-06	0.00163	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—CYP27A1—osteoporosis	9.67e-06	0.00161	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—LRP6—osteoporosis	9.53e-06	0.00158	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—PTHLH—osteoporosis	9.47e-06	0.00157	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—ACP5—osteoporosis	9.41e-06	0.00156	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	9.29e-06	0.00154	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—CALCA—osteoporosis	9.18e-06	0.00152	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—ATIC—osteoporosis	9.16e-06	0.00152	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—PNP—osteoporosis	9.16e-06	0.00152	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—IDH2—osteoporosis	8.93e-06	0.00148	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—TPI1—osteoporosis	8.75e-06	0.00145	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	8.67e-06	0.00144	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	8.55e-06	0.00142	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—POMC—osteoporosis	8.5e-06	0.00141	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—CYP27A1—osteoporosis	8.4e-06	0.00139	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—CALCA—osteoporosis	8.34e-06	0.00138	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—P4HB—osteoporosis	8.22e-06	0.00137	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—ACP5—osteoporosis	8.17e-06	0.00136	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—GAPDH—osteoporosis	8.07e-06	0.00134	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—TLN1—osteoporosis	8.05e-06	0.00134	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—RAP1A—osteoporosis	7.86e-06	0.0013	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—OXCT1—osteoporosis	7.79e-06	0.00129	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—CA2—osteoporosis	7.79e-06	0.00129	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—TPI1—osteoporosis	7.59e-06	0.00126	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—MGLL—osteoporosis	7.59e-06	0.00126	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—P4HB—osteoporosis	7.14e-06	0.00119	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—GAPDH—osteoporosis	7.01e-06	0.00116	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—P4HB—osteoporosis	6.94e-06	0.00115	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	6.86e-06	0.00114	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—RAP1A—osteoporosis	6.83e-06	0.00113	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—PTH—osteoporosis	6.75e-06	0.00112	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—RAP1A—osteoporosis	6.64e-06	0.0011	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—CNR2—osteoporosis	6.58e-06	0.00109	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—ADCY5—osteoporosis	6.53e-06	0.00108	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—NFATC1—osteoporosis	6.47e-06	0.00107	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—IDH2—osteoporosis	6.46e-06	0.00107	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—DKK1—osteoporosis	6.42e-06	0.00107	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—ENO1—osteoporosis	6.35e-06	0.00105	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—PSMA2—osteoporosis	6.26e-06	0.00104	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—PSMA5—osteoporosis	6.26e-06	0.00104	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—WNT1—osteoporosis	6.19e-06	0.00103	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—CYP27A1—osteoporosis	6.07e-06	0.00101	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—FGA—osteoporosis	6.02e-06	0.000999	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—ADCY5—osteoporosis	5.93e-06	0.000985	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—ACP5—osteoporosis	5.9e-06	0.00098	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—PTHLH—osteoporosis	5.6e-06	0.000929	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—BMP2—osteoporosis	5.6e-06	0.000929	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—ENO1—osteoporosis	5.52e-06	0.000916	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—TPI1—osteoporosis	5.49e-06	0.000911	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—FGB—osteoporosis	5.48e-06	0.000909	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—PSMA5—osteoporosis	5.44e-06	0.000903	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—PSMA2—osteoporosis	5.44e-06	0.000903	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—PSMA2—osteoporosis	5.29e-06	0.000878	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—PSMA5—osteoporosis	5.29e-06	0.000878	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Biological oxidations—POMC—osteoporosis	5.21e-06	0.000865	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—P4HB—osteoporosis	5.16e-06	0.000857	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—GAPDH—osteoporosis	5.07e-06	0.000841	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—RAP1A—osteoporosis	4.93e-06	0.000819	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—CALCA—osteoporosis	4.93e-06	0.000818	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—FDPS—osteoporosis	4.91e-06	0.000816	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—PKM—osteoporosis	4.91e-06	0.000816	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—POMC—osteoporosis	4.8e-06	0.000798	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—PGLS—osteoporosis	4.66e-06	0.000773	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—GPD2—osteoporosis	4.66e-06	0.000773	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—KL—osteoporosis	4.47e-06	0.000743	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—CYP19A1—osteoporosis	4.41e-06	0.000732	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—POMC—osteoporosis	4.36e-06	0.000724	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—ATIC—osteoporosis	4.26e-06	0.000707	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—PNP—osteoporosis	4.26e-06	0.000707	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—IL6R—osteoporosis	4.26e-06	0.000707	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—ADCY5—osteoporosis	4.15e-06	0.000689	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—GPX1—osteoporosis	4.14e-06	0.000687	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—ENO1—osteoporosis	3.99e-06	0.000662	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—PSMA2—osteoporosis	3.93e-06	0.000652	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—PSMA5—osteoporosis	3.93e-06	0.000652	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—MTHFR—osteoporosis	3.82e-06	0.000634	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—CA2—osteoporosis	3.62e-06	0.000601	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—OXCT1—osteoporosis	3.62e-06	0.000601	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—ADCY5—osteoporosis	3.6e-06	0.000598	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—GPX1—osteoporosis	3.59e-06	0.000596	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—MGLL—osteoporosis	3.53e-06	0.000586	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—ADCY5—osteoporosis	3.5e-06	0.000582	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—SPP1—osteoporosis	3.39e-06	0.000563	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—MTHFR—osteoporosis	3.31e-06	0.00055	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—CYP19A1—osteoporosis	3.19e-06	0.000529	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—IRS2—osteoporosis	3.07e-06	0.000509	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—POMC—osteoporosis	3.05e-06	0.000507	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—IDH2—osteoporosis	3e-06	0.000498	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—LEP—osteoporosis	3e-06	0.000498	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—ESR1—osteoporosis	2.86e-06	0.000476	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—CYP27A1—osteoporosis	2.82e-06	0.000468	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—ACP5—osteoporosis	2.75e-06	0.000456	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—IRS1—osteoporosis	2.68e-06	0.000444	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—POMC—osteoporosis	2.65e-06	0.00044	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—ADCY5—osteoporosis	2.61e-06	0.000433	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—GPX1—osteoporosis	2.6e-06	0.000431	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—POMC—osteoporosis	2.58e-06	0.000428	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—TPI1—osteoporosis	2.55e-06	0.000424	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—IL6R—osteoporosis	2.51e-06	0.000417	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—IGF1—osteoporosis	2.48e-06	0.000412	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—P4HB—osteoporosis	2.4e-06	0.000398	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—MTHFR—osteoporosis	2.4e-06	0.000398	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—GAPDH—osteoporosis	2.36e-06	0.000391	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—RAP1A—osteoporosis	2.29e-06	0.000381	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—POMC—osteoporosis	1.92e-06	0.000318	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—IL6—osteoporosis	1.9e-06	0.000315	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—ENO1—osteoporosis	1.85e-06	0.000308	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—PSMA5—osteoporosis	1.83e-06	0.000303	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—PSMA2—osteoporosis	1.83e-06	0.000303	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—MYC—osteoporosis	1.49e-06	0.000247	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—TGFB1—osteoporosis	1.49e-06	0.000247	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.48e-06	0.000246	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—ADCY5—osteoporosis	1.21e-06	0.000201	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—GPX1—osteoporosis	1.21e-06	0.0002	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—IL6—osteoporosis	1.12e-06	0.000186	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—MTHFR—osteoporosis	1.11e-06	0.000185	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—POMC—osteoporosis	8.91e-07	0.000148	CbGpPWpGaD
